| Serial Number | 98193395 |
| Word Mark | MYRIAD |
| Filing Date | Friday, September 22, 2023 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, September 24, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Medical test kits comprised primarily of chemical reagents for medical use and chemical preparations for medical purposes, namely, for detecting gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; Medical diagnostic reagents, medical diagnostic assays, diagnostic chemical preparations for medical purposes, namely, for genetic testing, cancer risk testing, prenatal testing, and diagnostic testing for diseases and disorders in the fields of reproductive health, oncology, urology, women's health, and mental health, and diagnostic test kits consisting primarily of reagents for medical diagnostic purposes, namely, testing of body fluids; Chemical reagents for medical use, namely, chemical reagents for use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; Diagnostic test kits comprised primarily of chemical reagents for medical use and chemical preparations for medical use, namely, diagnostic test kits for use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; Diagnostic kits comprised primarily of medical diagnostic reagents for the analysis of body fluids and the analysis of nucleic acid sequences for medical purposes and for detecting genetic conditions, disorders, and diseases for medical purposes |
| Goods and Services | Genetic testing services for diagnostic or treatment purposes; Genetic testing for medical purposes; Genetic counseling; Medical diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; Medical testing services, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; Medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; Medical diagnostic testing, monitoring, and reporting services; internet based health care information services; Providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; Providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing, individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis for medical purposes and medical and pharmaceutical consultation services related thereto, namely, discussion and interpretation with clients of medical test results and medical analysis related thereto; Medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental factors, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion and each medication's receptor activity, mechanism of action, and pathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication selection, personalize treatment options and choices for patients, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; Medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; Medical analysis services relating to the treatment of persons and medical consultation services which use bioinformatics for diagnostic or treatment purposes; Providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications |
| Goods and Services | Medical test kits comprised primarily of medical specimen collection devices in the nature of tubes and containers for the collection of patient specimens, printed test forms, printed mailing materials in the nature of cardboard boxes and envelopes of paper or plastic for packaging, and printed user medical information inserts being leaflets, cards, and questionnaires in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; sample preparation device for medical diagnostic uses; medical apparatus and instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of tissue-based diagnostic testing, cytology and cell-based testing; blood, urine, and saliva medical specimen collection kits comprised primarily of test tubes being human biological material, blood, urine, and saliva collecting tubes for medical purposes and self-mailer used for health and genetic analysis and diagnostics |
| Goods and Services | Clinical research in the field of genetics directed to the evaluation of genetic variants; Clinical research in the field of human genetics; Statistical analysis relating to scientific research in the field of human genetics and genetic variation; Scientific research services, namely, design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; Scientific research services, namely, statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; Scientific research in the nature of conducting clinical trials for others and medical research laboratory services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; Medical and scientific research in the field of biosignatures, genomics, proteomics and pharmacology; Scientific research services, namely, development of disease models for use in evaluation of drugs and discovery of new drugs; Drug discovery services; Drug screening for scientific research purposes, namely, for pre-clinical research and trials for pharmaceutical development purposes; Research and development in the field of new diagnostic products and pharmaceutical drug services for others; Biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; Providing temporary use of online non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; Scientific research analysis and scientific research consulting services in the field of bioinformatics; Gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | Tuesday, January 15, 2019 |
| First Use In Commerce Date | Tuesday, January 15, 2019 |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 10, 2023 |
| Primary Code | 010 |
| First Use Anywhere Date | Monday, September 30, 1996 |
| First Use In Commerce Date | Monday, September 30, 1996 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 10, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Friday, December 31, 1993 |
| First Use In Commerce Date | Friday, December 31, 1993 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 10, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | Saturday, January 31, 1998 |
| First Use In Commerce Date | Saturday, January 31, 1998 |
| Party Name | Myriad Genetics, Inc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Salt Lake City, UT 84116 |
| Event Date | Event Description |
| Tuesday, September 26, 2023 | NEW APPLICATION ENTERED |
| Wednesday, May 15, 2024 | ASSIGNED TO EXAMINER |
| Thursday, June 27, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, October 10, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 27, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, July 9, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, June 27, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, July 9, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, July 9, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, July 9, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, July 9, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, September 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, September 24, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, September 24, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |